Novartis has signed an agreement for the acquisition of all outstanding shares of US-based Avidity Biosciences for $12bn in cash on a fully diluted basis. This represents an enterprise value of close to $11bn at the expected closing date of the deal. Novartis has been proactively...

BioCryst Pharmaceuticals, Inc. announced it will acquire Astria Therapeutics, Inc., a biopharma company specializing in allergic and immunologic disease therapies, in a cash-and-stock deal valued at $13.00 per share, or approximately $700 million in enterprise value. Following...

Akero Therapeutics, Inc. a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has entered into a definitive agreement to be acquired by Novo Nordisk  for up to $5.2...